Caris Life Sciences, Inc. (CAI) on Thursday reported a sharp increase in fourth-quarter revenue and swung to profitability.
For the fourth quarter, revenue increased to $292.9 million from $129.9 million a year earlier. For the full year 2025, revenue rose to $812.0 million from $412.3 million in 2024.
The company posted net income of $82.0 million, or $0.28 per share, in the fourth quarter, compared with a net loss of $61.9 million, or $1.73 per share, a year earlier. For the full year 2025, net loss widened to $538.0 million, or $3.22 per share, compared with $378.3 million, or $10.66 per share, in the prior year.
For full-year 2026, Caris expects revenue in the range of $1.00 billion to $1.02 billion, representing growth of approximately 23% to 26% compared to 2025.
The company expects molecular profiling revenue to grow approximately 21% to 22% year over year in 2026, and pharma and research revenue to be in the range of $75 million to $85 million.
Caris also anticipates operating expenses of $590 million to $595 million in 2026 and expects to remain positive on free cash flow and adjusted EBITDA.
CAI is currently trading after market at $22.20, up $2.96 or 15.38 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.